| tetomilast (OPC-6535) / Otsuka |
NCT00317369: A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease |
|
|
| Terminated | 2 | 29 | Japan | OPC-6535(Tetomilast) | Otsuka Pharmaceutical Co., Ltd. | Crohn Disease | 07/07 | 08/07 | | |
NCT00317356: A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis |
|
|
| Terminated | 2 | 43 | Japan | OPC-6535(Tetomilast) | Otsuka Pharmaceutical Co., Ltd. | Colitis, Ulcerative | 08/07 | 08/07 | | |
NCT00917150: To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients |
|
|
| Completed | 2 | 771 | Japan, RoW | tetomilast (OPC-6535), placebo | Otsuka Pharmaceutical Co., Ltd. | Chronic Obstructive Pulmonary Disease | 04/14 | 04/14 | | |
EMPHASIS, NCT00874497: Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema |
|
|
| Terminated | 2 | 84 | US | tetomilast, placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Chronic Obstructive Pulmonary Disease | 07/15 | 08/15 | | |
